An OHSU study finds that access to U.S. residential addiction treatment centers for adolescents is limited and costly.

An editorial by Joanne Noon, Ph.D., RN, recommends the Journal Impact Factor no longer be a factor when considering nominations for nursing research awards: “It is time to move away from evaluating the quality of research based on the journal it was published in and instead evaluate the impact of the research itself.”

A study by OHSU and University of California-Davis Health finds members of historically marginalized communities have a higher risk of hospitalization and more aggressive, life-sustaining treatment near the end of their lives.

Joel Nigg, Ph.D., and co-authors write about how a parent’s life experiences may shape the expression of genes in their offspring even before a child is conceived.

A Forbes article details the background of how the drug nirogacestat received FDA approval for the treatment of desmoid tumors. Shivaani Kummar, M.D., who conducted the Phase 2 clinical trial study while at the National Cancer Institute, says: “Desmoid tumors can result in significant impact on functioning and quality of life of patients. Seeing the responses and clinical benefit reported by the investigators in the Phase I trial, I felt strongly that we should further evaluate this new drug for its likelihood to benefit patients with this rare tumor.”

OHSU researcheres leveraged a large national dataset and neuroimaging to confirm the brain-wide effects of ADHD. Michael Mooney, Ph.D., says, “By evaluating the cumulative effects of regions across the entire brain, we are now looking at ADHD as a whole-brain issue, which could make it easier to predict which kids have ADHD and how severe it may be. Down the road, we hope this will help with early identification of kids at most risk, so they can get the help they need as soon as possible.”

A Medriva story on the complexities of genetic testing for cancer highlights the collaboration between the OHSU Department of Molecular and Medical Genetics and the OHSU Knight Cancer Institute to offer services for patients with breast, ovarian and GI tract cancers.

An article by Salon about in increase in eating disorder diagnoses cites statistics from the OHSU Center for Women’s Health.

Elisa Boden, M.D., provides outside expert commentary on a study that found switching to medications that are biosimilar to the inflammatory bowel disease drug infliximab does not cause flare-ups. She says, “This study gives me data to be able to tell patients that they don’t need to worry if their insurance is requiring them to switch.”

An Axois story about Oregonians not getting enough sleep cites tips from OHSU.